Small cell carcinoma of the prostate (SmCC) is an extremely aggressive prostate malignancy showing neuroendocrine differentiation, accounting for less than 1% of all prostate cancers. It can arise de novo or more commonly develops through transdifferentiation from conventional acinar adenocarcinoma under prolonged androgen deprivation therapy (ADT) — this process is termed 'neuroendocrine transdifferentiation' or 'treatment-emergent neuroendocrine prostate cancer (t-NEPC)'. Clinically characterized by rapid progression, large mass, widespread metastases, and disproportionately low PSA level. The low serum PSA level is a diagnostic pitfall because SmCC does not produce PSA as it originates from neuroendocrine cells. Instead, chromogranin A and NSE (neuron-specific enolase) are elevated. On mpMRI, a large, heterogeneous, necrotic, and aggressive mass is seen; capsular and adjacent structure invasion is common. Median survival is 12-17 months; treatment is with cisplatin-based chemotherapy.
Age Range
60-80
Peak Age
70
Gender
Male predominant
Prevalence
Rare
Small cell carcinoma of the prostate develops through two distinct mechanisms. De novo SmCC originates directly from prostatic neuroendocrine stem cells — these are neuroendocrine cells found in small numbers in normal prostate epithelium that do not produce PSA and do not express androgen receptor. The more common mechanism, treatment-emergent transdifferentiation (t-NEPC), involves acinar adenocarcinoma cells transitioning to androgen receptor-independent survival pathways under prolonged ADT — through loss of RB1 and TP53 tumor suppressor genes, N-MYC amplification, and epigenetic reprogramming, the neuroendocrine phenotype is acquired. These neuroendocrine cells grow with dense cellular proliferation and minimal stroma — this structure forms the basis of marked diffusion restriction on MRI. The rapid tumor growth leads to inadequate vascular supply in the tumor center and coagulation necrosis — seen as necrotic non-enhancing areas on MRI. Absence of PSA production results from epigenetic silencing of the PSA gene promoter in neuroendocrine cells. Elevation of neuroendocrine markers such as chromogranin A and synaptophysin reflects the presence of neurosecretory granules.
Large, necrotic, aggressive mass in the prostate combined with disproportionately low PSA level and elevated chromogranin A/NSE — this clinical-radiological-laboratory triad is the pathognomonic combination of neuroendocrine prostate carcinoma (SmCC). While acinar adenocarcinoma produces PSA, SmCC produces neuroendocrine markers; this discordance is a diagnostic 'red flag'. Particular vigilance is needed in patients showing treatment-resistant progression under ADT.
Large (usually >4 cm), heterogeneous signal prostate mass on T2-weighted images. Viable tumor tissue shows T2 hypointense signal (dense cellularity), while necrotic areas show T2 hyperintense signal. The mass typically involves all prostate zones and zonal anatomy is completely obliterated. Capsular disruption, periprostatic fat invasion, and adjacent organ involvement (bladder base, rectum, seminal vesicles) frequently accompany. This aggressive appearance is distinctly different from the typically smaller and zone-confined appearance of acinar adenocarcinoma.
Report Sentence
A large, heterogeneous, necrotic mass is observed in the prostate; zonal anatomy is obliterated and capsular disruption is present — small cell carcinoma should be the leading consideration with low PSA.
Marked diffusion restriction in viable tumor tissue on DWI — hyperintense signal at high b values (b=1000-1500) and very low ADC values (typically <600 x 10⁻⁶ mm²/s) on ADC map. Necrotic areas show low signal on DWI and high values on ADC (T2 shine-through may occur but is differentiated by ADC). ADC values of SmCC are generally lower than acinar adenocarcinoma — reflecting denser cellularity. DWI findings are associated with high suspicion in PI-RADS v2.1.
Report Sentence
Marked diffusion restriction and very low ADC values (<600 x 10⁻⁶ mm²/s) are observed in viable tumor tissue on DWI, with necrotic areas showing high ADC — consistent with dense cellularity and small cell carcinoma should be considered.
Heterogeneous enhancement pattern on dynamic contrast-enhanced MRI: viable tumor tissue enhances (peripheral rim or heterogeneous pattern), while central necrotic areas do not enhance. Enhancement may be more prominent than acinar adenocarcinoma — reflecting aggressive neoangiogenesis. The proportion of non-enhancing necrotic areas is increased in large tumors. Enhancement in EPE and SVI regions indicates tumor invasion.
Report Sentence
Heterogeneous enhancement pattern is observed in the mass — peripheral enhancement with central necrotic non-enhancing areas — consistent with aggressive neuroendocrine tumor/small cell carcinoma.
Large, heterogeneous, necrotic mass extending beyond the prostate on CT. Peripheral enhancement with central necrotic low-density areas on contrast-enhanced CT. Direct invasion to the bladder base, rectum, or seminal vesicles is frequently seen. Pelvic, retroperitoneal, and/or distant lymphadenopathy, liver metastases, and visceral metastases may accompany. SmCC, unlike acinar adenocarcinoma, more frequently shows visceral metastases (liver, lung, brain) — bone metastases tend to be lytic rather than osteoblastic.
Report Sentence
A large, necrotic, heterogeneously enhancing mass extending beyond the prostate is observed on CT with adjacent organ invasion and visceral metastases — small cell carcinoma/neuroendocrine prostate carcinoma should be considered.
The mass appears generally isointense-to-hypointense on T1-weighted images. Intratumoral hemorrhage areas may appear as T1 hyperintense focal foci. T1 precontrast images provide reference for evaluation of necrosis and hemorrhage areas and interpretation of the enhancement pattern. Loss of periprostatic fat plane is best evaluated on T1 in large tumors.
Report Sentence
An isointense-to-hypointense mass is observed on T1-weighted images; focal hyperintense foci are consistent with intratumoral hemorrhage, and the periprostatic fat plane is obliterated.
Criteria
No prior adenocarcinoma diagnosis or ADT history. Originates directly from prostatic neuroendocrine cells. Rare (30-40% of SmCC cases). Usually diagnosed at advanced stage.
Distinct Features
Pure neuroendocrine morphology from the outset. PSA may have never been elevated. Aggressive course, presentation with widespread metastases.
Criteria
Prior acinar adenocarcinoma diagnosis + prolonged ADT (>12 months). Progression despite PSA decline under ADT. Chromogranin A/NSE elevation. RB1/TP53 loss, N-MYC amplification.
Distinct Features
Emerges in the context of ADT resistance. May have mixed histology (neuroendocrine + adenocarcinoma residual). Biopsy of newly growing lesions is diagnostic. Genomic profiling (ctDNA, biopsy) critical for treatment planning.
Criteria
SmCC + acinar adenocarcinoma components coexist. Both patterns seen on biopsy. PSA may be mildly elevated (due to acinar component) but disproportionately low relative to tumor burden.
Distinct Features
Heterogeneous mass on MRI — marked diffusion restriction in SmCC component, less prominent in acinar component. Treatment may require both chemotherapy (SmCC) and ADT (acinar).
Distinguishing Feature
Acinar adenocarcinoma is typically a smaller, zone-confined mass with elevated PSA. SmCC is a large, necrotic mass obliterating zonal anatomy with low PSA. Acinar adenocarcinoma causes osteoblastic bone metastases while SmCC shows lytic metastases and visceral metastases.
Distinguishing Feature
Lymphoma shows diffuse, homogeneous T2 hypointensity and homogeneous enhancement — necrosis is typically absent. SmCC is a heterogeneous, necrotic, and aggressive mass. Lymphoma shows homogeneous FDG uptake on PET-CT; SmCC shows heterogeneous uptake and necrosis. PSA is low in both but chromogranin A is not elevated in lymphoma.
Distinguishing Feature
Prostate abscess shows rim enhancement and central fluid/pus collection. SmCC is a heterogeneous solid mass and necrotic areas differ from fluid collections. Abscess may show diffusion restriction on DWI (pus viscosity) but clinical context (fever, dysuria, leukocytosis vs. weight loss, low PSA) is distinguishing.
Distinguishing Feature
Stromal tumor (STUMP/sarcoma) shows T2 hypointense solid mass but is generally not as large and necrotic as SmCC. PSA may be normal in stromal tumor but neuroendocrine markers are not elevated. SmCC's marked diffusion restriction and necrosis rate are higher than stromal tumors.
Urgency
emergentManagement
medicalBiopsy
NeededFollow-up
specialist-referralSmall cell carcinoma of the prostate requires emergent oncological consultation. Diagnosis must be confirmed by biopsy — synaptophysin, chromogranin A, CD56 positive on immunohistochemistry; PSA negative or weakly positive; Ki-67 very high (>50%). Staging is performed with whole-body CT/PET-FDG — bone scintigraphy may be insufficient (lytic metastases may be scintigraphy-negative). Treatment is similar to small cell carcinoma of the lung: cisplatin/carboplatin + etoposide chemotherapy. Radiotherapy can be added for local control. ADT alone is ineffective (neuroendocrine cells are androgen-independent). Novel targeted therapies are under investigation (DLL3, Aurora kinase inhibitors, PARP inhibitors). Prognosis is poor: median survival 12-17 months, 5-year survival <10%. In t-NEPC, prognosis is slightly better with prior ADT response and mixed histology.
Small cell prostate carcinoma is extremely aggressive with a median survival of 1-2 years. It is resistant to hormonal therapy (neuroendocrine origin). Treatment is cisplatin-based chemotherapy + radiation (similar to lung small cell Ca protocol). Osteolytic bone metastases differ from the osteoblastic metastases of adenocarcinoma.